selective IgA deficiency is more common among Jews than among other ethnic groups cannot be ruled out. It seems more likely, however, that the higher prevalence of selective IgA deficiency in the present series was related to the criteria for selection of patients to be examined.
Selective IgA deficiency has been detected mainly among patients with recurrent infections, "autoimmune" disorders, or malabsorption, but also among asymptomatic individuals (Bachman, 1968; Claman et al., 1966; Johansson et al., 1968; Cassidy et al., 1968) . The nature of the associated diseases in our patients with selective IgA deficiency was in general similar to that reported in the literature, but for the high incidence of hepatitis. At the time of diagnosis two patients had acute hepatitis, one had a documented history of this disease, one had chronic persistent hepatitis, and one had chronic active hepatitis.
IgA is believed to play an important part in protecting the gastrointestinal tract. Symptoms referrable to the gut, mainly malabsorption with steatorrhoea, have been observed in patients with selective IgA deficiency (Hobbs, 1968;  Crabbe and Heremans, 1967 ; Ammann and Hong, 1971 ). IgA-producing plasmacytes are dominant among the lymphoid cells of the lamina propria (Crabb6 and Heremans, 1967) , and evidence has been presented that IgA antibodies have viral neutralizing activity (Rossen et al., 1965) . Specific secre-tory IgA antibody to the hepatitis-associated antigen has indeed been detected in the mucosal surface by Ogra (1973) . It seems likely, therefore, that a defect in the normal protective action of IgA in the alimentary tract, combined with a mild defect in humoral immunity, could result in a higher tendency to infections by viruses, the portal of entry of which is the gut.
We are not aware of any previous reports of a higher susceptibility of patients with selective IgA deficiency to viral hepatitis. "Lupoid" hepatitis, however, has been reported so far in five patients with selective IgA deficiency (Ammann and Hong, 1971) , and one of our patients had chronic aggressive hepatitis. It is conceivable that the "immunological imbalance," postulated by Hobbs (1968) British Medical Journal, 1973, 4, 763-766 Summary Seven types of digoxin 0 25 mg tablet in common use in the United Kingdom were administered to a total of 38 patients. Significant differences were found in the mean plasma digoxin levels and in the control of atrial fibrillation achieved with these brands. There was a close correlation between the dissolution rate of the tablets and the plasma digoxin levels. Measurement of in-vitro dissolution rate appears to be a valid method of ensuring that different tablets of digoxin are of equal efficacy. However, in some patients absorption of the drug is markedly sensitive to changes in dissolution rate and new pharmacopoeal standards should not be defined until very rapidly-dissolving formulations have been studied.
Introduction
It has become apparent that tablets of digoxin may contain the correct dose but provide only a portion of this dose for absorption by the patient. Reports from several countries have shown wide variation in absorption between different brands of tablets and even between different batches of the same brand (Lindenbaum et al., 1971; Manninen et al., 1971; Bertler et al., 1972; Shaw et al., 1972) . These differences are not detected by the test for disintegration rate given in the British and U.S. pharmacopoeias Wagner et al., 1973) .
We have administered to patients seven different types of digoxin tablet used in the United Kingdom and have recorded the plasma digoxin levels and clinical response obtained with each type. The digoxin level and response have been compared with the dissolution rate of the tablets to assess the validity of measurement of dissolution rate as an in-vitro test for quality control of digoxin tablet manufacture.
Patients and Methods Of the two groups of 20 patients studied 19 of each group completed the period of study (table I) . Each patient used four different types of digoxin 025 mg tablet, each type for a two-week period. The sequence was randomized. The dosage of digoxin was constant for each patient. The patients were asked to take the daily dose in the latter half of the evening and at the same time each day.
Blood samples were taken at the end of each two-week period and plasma digoxin was measured by radioimmunoassay (Chamberlain et al., 1970) . To avoid the absorptive and distribution phases blood was always taken more than 10 hours after the last dose. The mean interval since the last dose was 13 hours (range 10-17 hr) and was approximately constant for each patient. A 30-second E.C.G. rhythm strip at rest was recorded on each visit.
The number of tablets supplied to each patient was known, and from a count of the unused tablets the discrepancy in self-administration was estimated. The patient's other medication was unchanged throughout the time of the study. (Jensen, 1953) . Six tablets were used for measurement of dissolution rate and for each batch the test was repeated on three separate occasions.
Results
The mean plasma digoxin levels obtained with the seven types of tablet are given in table II. To permit comparison between all types the levels achieved wi-th the newer Lanoxin have been taken as 100 and the other mean levels expressed as a proportion of this figure. The levels found with newer Lanoxin were 430/,, higher than those recorded with the tablets (older Lanoxin) which produced lowest levels. Analysis of variance showed that the differences within each group were statistically significant (P < 0-1).
The discrepancy in the tablet count of each type was always small (< 3%) and was similar for each type of tablet within the two groups.
Thirteen patients in each group had atrial fibrillation. The ventricular rates and digoxin levels recorded in these patients during the different digoxin treatments are given in table III. These differences are statistically significant (analysis of variance, P < 0 01). The dissolution rates of the tablets are given in Some patients appeared to be much more sensitive than others to change in the dissolution of their tablets. The change in digoxin level in two patients from the second group who had both taken 05 mg digoxin per day is shown in fig. 3 . Both had normal blood urea and serum creatinine and were 765 of similar weight. Patient A absorbed digoxin poorly from the slowly-dissolving tablets but had a marked increase in plasma digoxin level when changed to the faster-dissolving tablets: patient B had a higher digoxin level with slowlydissolving tablets and showed only a moderate increase during use of the faster-dissolving brands. (1785) noted that the efficacy of the foxglove leaves varied according to the season and age of the plants, and observed that some physicians had avoided toxicity by using relatively inert roots.
With the introduction of digoxin it was hoped that a more consistent preparation would be possible (Wayne, 1933) . Later, however, Gold et al. (1953) noted the difference in the recommended doses of digoxin and suggested that this might reflect variation in the preparations used. Occasional cases were reported where parenteral doses were much more effective than administration by mouth (Craig et al., 1958) .
It has now become clear that wide variation in the absorption of digoxin may result from differences in the type of tablet used. This variation appears to be due to the effect of the production methods on the particle size of the digoxin (Shaw et al., 1973 b) . Our results confirm that there are important differences in the steady-state plasma digoxin levels achieved during maintenance treatment with different types of 0-25 mg digoxin tablets available in the United Kingdom. They slightly underestimate the magnitude of difference since some patients with very poor absorption of digoxin from slowly-dissolving tablets were already investigated and not included in this study . Digoxin levels recorded six to 24 hours after the last dose have been found to correlate with the clinical effect and toxicity of digoxin (Smith, 1972) . These differences render treatment with digoxin more hazardous since the dose found to be satisfactory with one brand may produce toxicity or underdigitalization when the patient later receives tablets of another brand. Measurement of plasma digoxin levels in cardiac patients after a suitable period of maintenance dosage is probably the most clinically relevant means of quantitating differences in the efficacy of tablets. Differences have also been found in the peak levels and the areas under absorption curves in single-dose studies: these indices appear to be very sensitive ways of detecting non-equivalence of formulations but produce differences larger than those recorded after periods of daily digoxin administration (Lindenbaum et al., 1971; Falch et al., 1973; Lindenbaum et al., 1973) .
Differences were also seen in the clinical response to the digoxin treatment in patients with atrial fibrillation. The variation in mean ventricular rate underestimates the non-equivalence of clinical response in individual patients since some patients tend to have persistently slow ventricular rates at rest even when not using digitalis.
Despite the differences in biological availability of the tablets studied, all passed the test for disintegration time given in the British Pharmacopoeia. This test, which measures the time taken by the tablets to fragment, is now regarded as an inadequate means of preventing non-equivalence of brands of tablet. The dissolution rate measures the rate at which the drug enters solution and estimates a property of tablets more directly related to the needs of absorption. Our data show that there is a close correlation between the digoxin level achieved in patients during maintenance therapy and the dissolution rate of the tablets used, even when the tablets are produced by various manufacturing methods and contain a variety of combinations of excipient substances. Similar correlation between dissolution rate and steady-state levels in normal volunteers have been found by Lindenbaum et al. (1973) and Johnson et al. (1973) . We have found appreciable batchto-batch variation in dissolution rate of some of the brands studied (Shaw, 1973) , indicating (that keeping to the use of one brand will not always guarantee consistent bioavailability. Lindenbaum et al. (1973) and Johnson et al. (1973) proposed that a minimal acceptable level of dissolution rate be established. It appears that a dissolution rate of greater than 80% at 1 hour would ensure that variation was less than 0-1 ng/ml in the mean digoxin level of a group of subjects. However, -ome patients show a pronounced rise in plasma digoxin level when the dissolution rate of their tablets is increased, and are at risk from even moderate degrees of variation between tablets. Others absorb digoxin well even from slowlydissolving tablets. These differences between subjects, which have also been observed in other studies Falch et al., 1973) , may reflect individual variation in gastrointestinal transit time. A similar variation between patients is known for a variety of drugs which, like digoxin, are poorly soluble (Levy, 1968) . The sensitivity of some patients to differences in the rate of dissolution of the tablets means that standards designed to ensure the therapeutic equivalence of digoxin tablets for all patients should be as strict as possible.
The linear relation between absorption and dissolution rate is unlikely to continue indefinitely since only 100% of the dose can ultimately be absorbed. With progressively faster dissolution rates the amount absorbed could reach a plateau, and
